Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Looks To Lead World In Post-Market Device Surveillance With Safety Plan, Investments

Executive Summary

US FDA Nov. 20 announced plans for a broad series of updates to its Medical Device Safety Action Plan for the next several months, with the goal that FDA "is consistently first among the world’s regulatory agencies to identify and act upon safety signals related to medical devices.


Related Content

US Regulatory Roundup, November 2018: Press Scrutiny, FDA Reforms And The Midterms
Study Highlights Autoimmune, CTD Issues In Women Who Had Breast Implants
NEST Test Cases Could Support Company Submissions And Determine Future Of National Device Database
Public Interest Groups Will Leverage ‘Bleeding Edge’ Lessons To Push For Device Safety Changes
Device Firms’ ‘Vaginal Rejuvenation’ Marketing Claims Spark US FDA Response
Boston Scientific Wins Pelvic Mesh Bellwether
Jury Awards Plaintiff $68M In Bard Mesh Case
New Safety Framework Mixes Current Efforts, New Investments At US FDA
Metal-On-Metal Hips Get Failing Grade In New Registry Analysis


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts